Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1038620170350020172
Radiation Oncology Journal
2017 Volume.35 No. 2 p.172 ~ p.179
Stereotactic body radiation therapy for liver oligo-recurrence and oligo-progression from various tumors
Cha Yu-Jin

Kim Mi-Sook
Jang Won-Il
Seo Young-Seok
Cho Chul-Koo
Yoo Hyung-Jun
Paik Eun-Kyung
Abstract
Purpose: To evaluate the outcomes of stereotactic body radiation therapy (SBRT) for patients with liver oligo-recurrence and oligo-progression from various primary tumors.

Materials and Methods: Between 2002 and 2013, 72 patients with liver oligo-recurrence (oligo-metastasis with a controlled primary tumor) and oligo-progression (contradictory progression of a few sites of disease despite an overall tumor burden response to therapy) underwent SBRT. Of these, 9 and 8 patients with uncontrollable distant metastases and patients immediate loss to follow-up, respectively, were excluded. The total planning target volume was used to select the SBRT dose (median, 48 Gy; range, 30 to 60 Gy, 3?4 fractions). Toxicity was evaluated using the Common Toxicity Criteria for Adverse Events v4.0.

Results: We evaluated 55 patients (77 lesions) treated with SBRT for liver metastases. All patients had controlled primary lesions, and 28 patients had stable lesions at another site (oligo-progression). The most common primary site was the colon (36 patients), followed by the stomach (6 patients) and other sites (13 patients). The 2-year local control and progression-free survival rates were 68% and 22%, respectively. The 2- and 5-year overall survival rates were 56% and 20%, respectively. The most common adverse events were grade 1?2 fatigue, nausea, and vomiting; no grade ¡Ã3 toxicities were observed. Univariate analysis revealed that oligo-progression associated with poor survival.

Conclusion: SBRT for liver oligo-recurrence and oligo-progression appears safe, with similar local control rates. For liver oligo-progression, criteria are needed to select patients in whom improved overall survival can be expected through SBRT.
KEYWORD
Liver metastases, Oligo-recurrence, Oligo-progression, Stereotactic radiation therapy
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø